Yazar "Ozturk, Vesile" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Efficacy and Safety of 400 and 800mg Etodolac vs. 1,000mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double-blind, Crossover, Multicenter, Phase III Clinical Trial
    (Wiley-Blackwell, 2013) Ozturk, Vesile; Ertas, Mustafa; Baykan, Betul; Sirin, Hadiye; Ozge, Aynur
    Aim: We aimed to determine the efficacy and safety of etodolac, in acute migraine attacks in comparison with paracetamol (acetaminophen). Methods: We designed a randomized, double-blind, crossover phase III clinical trial for patients diagnosed with migraine for at least 1year, according to ICHD-II criteria. Two hundred and twenty-nine adult patients having 2 to 8 attacks monthly from 17 centers were included. The patients were instructed to use 3 attack treatment packages consisting of 1,000mg paracetamol, 400mg etodolac, and 800mg etodolac on 3 migraine attacks of moderatesevere intensity each in a 3-month treatment period, interchangeably. Results: Any pain medication was used in 1,570 migraine attacks while study treatments were used in 1,047 attacks. The results for 1,000mg paracetamol, 400 mg etodolac, and 800 mg etodolac were as follows: response of headache at 2hours 44.9%, 48.3% and 46.1%; pain-free at 2hours 19.2%, 19.3% and 24.1%; sustained pain-free from 2 to 24hours 34.3%, 38.3% and 41.1%; relapse rates in 2 to 24hours 7.3%, 14.3% and 9.7%. There were no statistically significant differences between the groups regarding the headache response, pain-free, sustained pain-free, and relapse rates. Nausea, vomiting, phonophobia, or photophobia decreased similarly in all groups within 24hours of treatment administration. Drug-related adverse events were noted in 8 patients with 1,000mg paracetamol, in 9 patients with 400mg etodolac and in 9 patients for 800mg etodolac during the study. Comment: Our study showed that etodolac is a safe and effective alternative in acute migraine treatment and showed comparable efficacy to paracetamol 1,000mg. Etodolac may be considered as an alternative option for acute treatment of migraine.
  • Küçük Resim Yok
    Öğe
    Efficacy and Safety of 400 and 800mg Etodolac vs. 1,000mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double-blind, Crossover, Multicenter, Phase III Clinical Trial
    (Wiley-Blackwell, 2013) Ozturk, Vesile; Ertas, Mustafa; Baykan, Betul; Sirin, Hadiye; Ozge, Aynur
    Aim: We aimed to determine the efficacy and safety of etodolac, in acute migraine attacks in comparison with paracetamol (acetaminophen). Methods: We designed a randomized, double-blind, crossover phase III clinical trial for patients diagnosed with migraine for at least 1year, according to ICHD-II criteria. Two hundred and twenty-nine adult patients having 2 to 8 attacks monthly from 17 centers were included. The patients were instructed to use 3 attack treatment packages consisting of 1,000mg paracetamol, 400mg etodolac, and 800mg etodolac on 3 migraine attacks of moderatesevere intensity each in a 3-month treatment period, interchangeably. Results: Any pain medication was used in 1,570 migraine attacks while study treatments were used in 1,047 attacks. The results for 1,000mg paracetamol, 400 mg etodolac, and 800 mg etodolac were as follows: response of headache at 2hours 44.9%, 48.3% and 46.1%; pain-free at 2hours 19.2%, 19.3% and 24.1%; sustained pain-free from 2 to 24hours 34.3%, 38.3% and 41.1%; relapse rates in 2 to 24hours 7.3%, 14.3% and 9.7%. There were no statistically significant differences between the groups regarding the headache response, pain-free, sustained pain-free, and relapse rates. Nausea, vomiting, phonophobia, or photophobia decreased similarly in all groups within 24hours of treatment administration. Drug-related adverse events were noted in 8 patients with 1,000mg paracetamol, in 9 patients with 400mg etodolac and in 9 patients for 800mg etodolac during the study. Comment: Our study showed that etodolac is a safe and effective alternative in acute migraine treatment and showed comparable efficacy to paracetamol 1,000mg. Etodolac may be considered as an alternative option for acute treatment of migraine.
  • Küçük Resim Yok
    Öğe
    Is there an association between migraine and atopic disorders? The results of multicenter migraine attack study
    (Journal Neurological Sciences, 2008) Ozge, Aynur; Ozturk, Candan; Dora, Babuer; Inan, Levent; Saip, Sebahattin; Ozturk, Musa; Vanli, Ebru Nur; Gokcay, Figen; Ozturk, Vesile; Erdemoglu, Ali Kemal; Tasmertek, Fazilet; Yilmaz, Nurguel; Ozer, Gokhan; Siva, Aksel; Demir, Nurhak; Baykan, Betuel; Guler, Ayse; Poyraz, Turan; Doner, Hatice; Sirin, Hadiye
    We designed this multicenter study to evaluate the abnormalities related to the mast cell activation during attacks in a large group of migraineurs and to compare the findings both with episodic tension type headache (ETTH) and matched healthy control subjects. After the evaluation of diagnostic criteria, 213 subjects were included in this study after giving consent. Of all 146 subjects (67.8%) were migraineurs, 38 (19.4%) were ETTH patients and 29 others were healthy controls matched according to age and sex. Immunological screening showed significantly high ratios of IL-beta, IL-2, IL-6 and TNF-alpha in the migraine group compared to ETTH (16.6% vs 10.5%, 20.0% vs 5.3%, 13.8% vs 2.6% and 15.9% vs 5.3%, respectively) and to the healthy controls. Logistic regression analysis showed that only duration of headache has an important effect on having IL-2 abnormality (Exp-B: 0.322, 95% CI: 0.151-0.688, p=0.003) in patients with migraine. There was no important effect of clinical variables on serological abnormalitites or each other. In conclusion, our multicenter clinical and laboratory based study suggests that primary headache disorders (migraine and ETTH) are associated with atopic changes and they might share the inflammatory mechanism (pro-inflammatory as well as anti-inflammatory cytokine abnormalities) during headache attacks.